Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer

Clinical and Translational Oncology

Volumn 15, Issue 4, 2013, Pages 265-270

  Villarejo Campos, Pedro ^a   Padilla Valverde, David ^a   Martin, Raúl Martin ^b   Menéndez Sánchez, Pablo ^a   Cubo Cintas, Teófilo ^a   Bondia Navarro, Jose Antonio ^c   Fernández, Jesús Martín ^a  

^a Hospital Universitario de Ciudad Real   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

Angiogenesis; Gastric cancer; Lymph node metastasis; Lymphangiogenesis; Serum VEGF; Serum VEGF C; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL PLUS FOLINIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AGED; ARTICLE; BINDING AFFINITY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGOGASTRECTOMY; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RADIATION DOSE; STOMACH CANCER; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84876474637     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0908-x     Document Type: Article

References (32)

1. Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71
2. Cheong JH, Hong SY, Zheng Y, Noh SH (2011) Eupatilin inhibits gastric cancer cell growth by blocking STAT3-mediated VEGF expression. J Gastric Cancer 11:16-22
3. Osinsky S, Bubnovskaya L, Ganusevich I, Kovelskaya A, Gumenyuk L, Olijnichenko G et al (2011) Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin Transl Oncol 13:133-138
4. Christopoulos A, Ahn SM, Klein JD, Kim S (2011) Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck 33:1220-1229
5. Al-Rawi MA, Mansel RE, Jiang WG (2005) Molecular and cellular mechanisms of lymphangiogenesis. Eur J Surg Oncol 31:117-121
6. Nagahashi M, Ramachandran S, Rashid OM, Takabe K (2010) Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol 16:4003-4012
7. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A et al (2004) p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206-215
8. Chen J, Li T, Wu Y, He L, Zhang L, Shi T et al (2011) Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol 137:1799-1812
9. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D et al (2003) Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89:426-430
10. Han FH, Li HM, Zheng DH, He YL, Zhan WH (2010) The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 36:1172-1179
11. Ding S, Lin S, Dong X, Yang X, Qu H, Huang S et al (2005) Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer. In Vivo (Athens, Greece) 19:793-795
12. Werther K, Christensen IJ, Nielsen HJ (2002) Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 86:417-423
13. Bouvier AM, Sant M, Verdecchia A, Forman D, Damhuis R, Willem Coebergh J et al (2010) What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer 46:1086-1092
14. Bentrem D, Gerdes H, Tang L, Brennan M, Coit D (2007) Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 14:1853-1859
15. Washington K (2010) 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17:3077-3079
16. Mazumdar M, Smith A, Bacik J (2003) Methods for categorizing a prognostic variable in a multivariable setting. Stat Med 22:559-571
17. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E et al (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100:270-278
18. Karayiannakis AJ, Bolanaki H, Syrigos KN, Asimakopoulos B, Polychronidis A, Anagnostoulis S et al (2003) Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 194:119-124
19. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ (2004) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100:1385-1392
20. Carrillo-de Santa Pau E, Carrillo Arias F, Caso Pelaez E, Muguruza Trueba I, Sanchez Hernandez I, Munoz Molina GM et al (2009) Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 28:393-398
21. Zusterzeel PL, Span PN, Dijksterhuis MG, Thomas CM, Sweep FC, Massuger LF (2009) Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. J Cancer Res Clin Oncol 135:283-290
22. Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R et al (2009) High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 96:1443-1451
23. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C et al (2002) Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236:37-42
24. Tamura M, Ohta Y (2003) Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 98(6):1217-1222
25. Yu XM, Lo CY, Lam AK, Leung P, Luk JM (2008) Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 247:483-489
26. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Banas T (2007) Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 249:171-177
27. Wang TB, Deng MH, Qiu WS, Dong WG (2007) Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 13:1794-1797
28. Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J et al (2009) High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res 15:1741-1746
29. Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J (2009) Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. Int J Colorectal Dis 24:269-274
30. Sung JY, Lee S, Kim YW, Park YK (2008) Vascular endothelial growth factor receptor-3 is a favorable prognostic factor in advanced gastric carcinoma. Oncol Rep 19:939-944
31. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D (2009) Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 45:1407-1414
32. Kirk R (2011) Targeted therapies: should we be aghast at the AVAGAST data? Nat Rev Clin Oncol 8:567